
Biogen looks to its bench to replace chairman Papadopoulos; Lilly, AbbVie gene therapy partner makes CSO hire
→ Caroline Dorsa will chair the board at Biogen after its annual meeting in June, the company revealed on Wednesday. Last month, Stelios Papadopoulos said he would retire from the post that he’s held since 2014. Dorsa, a board member at Biogen since 2010, concluded her 21-year career at Merck as SVP, global human health, strategy and integration from 2008-09. She also has board seats at Intellia and Illumina.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.